Splash Beverage Group, Inc.（EDVA）資訊與事件EDVASplash Beverage Group, Inc.

Selling Stockholders Offer Up to 1.01M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.01M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Endovia's CannEpil Receives FDA Minor Use Qualification

Endovia Health Sciences announced the FDA Center for Veterinary Medicine determined that the proposed use of CannEpil, an investigational CBD and THC oral solution for control of pain associated with bone cancer in dogs, qualifies as a minor use under the Minor Use and Minor Species program. The determination establishes CannEpil eligibility to pursue the conditional approval pathway for this indication, with minor-use status maintained through approval of the applicable New Animal Drug Application. Endovia and Lupvindol are scheduled to meet with the FDA on November 19 for a Pre-Submission Conference on the CannEpil development program. In parallel, the companies are sourcing U.S. manufacturing for CannEpil, with a potential veterinary commercial launch in 2027 subject to regulatory approval. CannEpil remains investigational and has not been approved or conditionally approved by the FDA. Brady Cobb, interim CEO of Endovia, said, "This determination represents an important regulatory milestone for CannEpil and provides greater clarity around the pathway we are pursuing with the FDA."